These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38738774)

  • 21. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
    Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
    Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
    Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
    Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.
    Kataoka S; Takaishi M; Nakajima K; Sano S
    J Dermatol Sci; 2020 Dec; 100(3):230-233. PubMed ID: 33109421
    [No Abstract]   [Full Text] [Related]  

  • 26. Psoriasis improvement and satisfaction in patients using a clobetasol spray and oral apremilast combination regimen: A pilot study.
    Wei C; Friedman AJ; Prussick RB
    J Am Acad Dermatol; 2020 Oct; 83(4):1198-1200. PubMed ID: 32088274
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
    Vico-Alonso C; Sánchez-Velázquez A; Pinilla-Martin B; Andrés-Lencina JJ; Aragón-Miguel R; Calleja-Algarra A; Rivera-Díaz R
    Int J Dermatol; 2020 Apr; 59(4):e102-e103. PubMed ID: 31347142
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
    J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
    Artamonova OG; Karamova AE; Nikonorov AA; Verbenko DA; Vasileva EL; Kubanov AA
    Bull Exp Biol Med; 2021 May; 171(2):208-211. PubMed ID: 34173094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
    Sacchelli L; Patrizi A; Ferrara F; Bardazzi F
    Dermatol Ther; 2018 Nov; 31(6):e12719. PubMed ID: 30358044
    [No Abstract]   [Full Text] [Related]  

  • 34. Three cases of palmoplantar pustulosis successfully treated with apremilast.
    Eto A; Nakao M; Furue M
    J Dermatol; 2019 Jan; 46(1):e29-e30. PubMed ID: 29905386
    [No Abstract]   [Full Text] [Related]  

  • 35. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
    Schafer PH; Chen P; Fang L; Wang A; Chopra R
    J Immunol Res; 2015; 2015():906349. PubMed ID: 25973439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
    Moustafa F; Feldman SR
    Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
    Cho M; Honda T; Ueshima C; Kataoka T; Otsuka A; Kabashima K
    Acta Derm Venereol; 2018 Nov; 98(10):975-976. PubMed ID: 29944172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.